Table 3. Treatment outcomes according to the latent tuberculosis infection treatment regimens.
| Variable | 9H (n = 43) | 3HR (n = 81) | 4R (n = 13) | P valuea | |
|---|---|---|---|---|---|
| Total number of visits, median (IQR) | 6 (5–7) | 3 (3–4) | 4 (4–4) | <0.001 | |
| Number of visits in patients without adverse events | 5 (5–5) | 3 (3–3) | 4 (4–4) | <0.001 | |
| Number of visits in patients with adverse events | 7 (6–9) | 4 (3–5) | 4 (4–NA) | <0.001 | |
| Time to treatment interruption, median (IQR) | 103 (25–143) | 23 (6–93) | 31 (NA) | 0.16 | |
| Treatment outcome, n (%) | |||||
| Complete without a change in the 1st regimen | 34 (81.0) | 74 (90.2) | 12 (92.3) | 0.03 | |
| Complete with a change in the 1st regimen | 8 (18.6) | 7 (8.6) | 0 | 0.15 | |
| Incomplete | 2 (4.7) | 0 | 1 (7.7) | 0.12 | |
Data are presented as number of healthcare workers (%), unless otherwise specified.
aP value for comparison between the 9-month isoniazid and 3-month isoniazid/rifampin.
9H, 9-month isoniazid; 3HR, 3-month isoniazid/rifampin; 4R, 4-month rifampin; IQR, interquartile range; NA, not applicable.